Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1638 1653
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17997429 | MODEL-BASED CONTROL FOR COLUMN-BASED CONTINUOUS VIRAL INACTIVATION OF BIOPHARMACEUTICALS | Non-Final OA | Massachusetts Institute of Technology |
| 17995671 | INTEGRATION OF LARGE ADENOVIRUS PAYLOADS | Final Rejection | University of Washington |
| 18506193 | SYNTHETIC NUCLEIC ACIDS INCLUDING ASTROCYTE-DIRECTED PROMOTER CONSTRUCTS AND METHODS OF USING THE SAME | Non-Final OA | Eli Lilly and Company |
| 18069621 | CIRCULAR RNA COMPOSITIONS AND METHODS | Final Rejection | Orna Therapeutics, Inc. |
| 17929574 | COMPOSITIONS AND METHODS FOR ANALYTE DETECTION | Non-Final OA | Colorado State University Research Foundation |
| 18118072 | METHODS AND COMPOSITIONS FOR DETECTING RISK OF CANCER RELAPSE | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17292923 | METHODS FOR INDUCING IMMUNE TOLERANCE | Non-Final OA | Translate Bio, Inc. |
| 18029112 | Use of an intervertebral disc fibrosis-inducing substance in preparation of medication | Non-Final OA | Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine |
| 18537897 | BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER | Non-Final OA | Synlogic Operating Company, Inc. |
| 18326637 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | Non-Final OA | Synlogic Operating Company, Inc. |
| 18515458 | CHIMERIC ANTIGEN RECEPTOR | Non-Final OA | AUTOLUS LIMITED |
| 18321517 | Cell | Non-Final OA | AUTOLUS LIMITED |
| 18282061 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRHYTHMOGENIC CARDIOMYOPATHY | Final Rejection | UCL BUSINESS LTD |
| 18558669 | EXTRACELLULAR VESICLE-DIRECTED POLYPEPTIDE TAG | Non-Final OA | Ottawa Hospital Research Institute |
| 18558226 | METHOD FOR PRODUCING VASCULARIZED BIOLOGICAL TISSUE | Non-Final OA | Universitaet des Saarlandes |
| 18285560 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS | Non-Final OA | Spirovant Sciences, Inc. |
| 18238074 | POLYMERIC MICELLE COMPOSITIONS | Non-Final OA | UVic Industry Partnerships Inc.- Univ. of Victoria |
| 18251368 | TENASCIN-C AUTOANTIGENIC EPITOPES IN RHEUMATOID ARTHRITIS | Non-Final OA | Benaroya Research Institute at Virginia Mason |
| 18310788 | CANCER ERADICATING - BIO-NANOPARTICLES (CE-BNP) | Non-Final OA | ATHANOR BIOSCIENCES, INC. |
| 18050834 | METHODS AND COMPOSITIONS FOR THE PURIFICATION OF ADENO-ASSOCIATED VIRUS | Non-Final OA | Oxford Biomedica (US) LLC |
| 18050089 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | Non-Final OA | JPV01 LTD. |
| 17272631 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS | Non-Final OA | Exuma Biotech Corp. |
| 17179931 | COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS | Final Rejection | Sixfold Bioscience Ltd. |
| 17439921 | EXPRESSION CONSTRUCTS FOR THE GENETIC MODIFICATION OF CELLS | Final Rejection | Deutsches Krebsforschungszentrum |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy